Announcements

Clinuvel's company releases, including archives.

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited. Class Number Exercise price CUVAK Conditional Performance Rights subject to various performance milestones 50,000 $Nil Consequently, there are now 1,341,482 unlisted conditional performance rights on issue. - End - Investor relations contacts: Australia: Clinuvel Pharmaceuticals Limited, T: +61 3 9660 4900Europe: Clinuvel AG, T: +41 41 763 54 30Email About Clinuvel Pharmaceuticals LimitedClinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on…
In accordance with ASX listing rules 3.13.1 and 14.3, Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced it will hold its 2014 Annual General Meeting of shareholders on Friday November 28, 2014 at 10.00am AEST at Karstens Conference Centres, Level 8, Room 803, 123 Queen Street, Melbourne, Victoria, Australia 3000 A formal Notice of Meeting and the Company’s Annual Report will be lodged with the ASX no later than October 27, 2014. – End – Investor relations contacts: Australia: Clinuvel Pharmaceuticals Limited, T: +61 3 9660 4900Europe: Clinuvel AG, T: +41 41 763 54 30Email About Clinuvel…
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that data from the use of its drug SCENESSE® (afamelanotide 16mg) in clinical trials and special access schemes are being presented at the European Academy for Dermatology and Venereology (EADV) meeting in Amsterdam, held from 8-12 October. Results from the Phase II US study in vitiligo (CUV102) and clinical experiences of treating erythropoietic protoporphyria (EPP) patients during seven years in Switzerland and Italy are being discussed among specialists and dermatologists at the ‘MSH Society Meeting’ on October 8. This is the sixth consecutive year that clinical data from physicians…
Friday, 26 September 2014 07:28

Clinuvel: EMA Oral Explanation

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has attended the plenary meeting of the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) in London. The meeting was held as part of the scientific review of the marketing authorisation application (MAA) for SCENESSE® (afamelanotide 16mg) as a potential therapy for adult patients diagnosed with the orphan disease erythropoietic protoporphyria (EPP). The EPP patient community was represented during this meeting. An outcome may be expected during the plenary session of the CHMP in October. - End - Investor relations contacts: Australia: Clinuvel…
CHMP meeting scheduled September 23 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it will present at the plenary meeting of the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) in London. Clinuvel’s presentation to all CHMP members (and/or alternates) forms part of the EMA’s review of the marketing authorisation application (MAA) of Clinuvel’s drug SCENESSE® (afamelanotide 16mg) for the preventative treatment of the orphan disease erythropoietic protoporphyria (EPP). The Oral Explanation is scheduled for September 23. Clinuvel filed the MAA with the EMA in February 2012. - End - Investor relations…
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that results from its US Phase IIa study of SCENESSE® (afamelanotide 16mg) in vitiligo (CUV102) have been published in the peer-reviewed Journal of the American Medical Association-Dermatology (e-pub doi:10.1001/jamadermatol.2014.1875). Vitiligo is a skin disorder caused by the total or partial loss of function of pigment producing cells of the skin (melanocytes). As a result, lighter depigmented patches of skin (lesions) appear due to the loss of pigment (melanin). CUV102, an open-label Phase IIa study conducted in three US expert centres (The Vitiligo & Pigmentation Institute of Southern California in…
Development of pediatric formulations for EPP and a topical melanocortin peptide [CUV9900] for dermatology ClinuvelPharmaceuticalsLimited (ASX:CUV;XETRA-DAX:UR9;ADR:CLVLY) today announced that it has reached agreement on terms and conditions with Biotech Lab Singapore (BLS) Pte Ltd to enter a joint venture (to be called Vallaurix Pte Ltd) for the final development of formulations for paediatric use of afamelanotide, and CUV9900, a novel melanocortin peptide for topical application for skin care. Clinuvel retains a majority interest in the partnership. The financial terms have not been disclosed. In the joint venture, Clinuvel will lead and oversee the scientific aspects including the regulatory development of…
Tuesday, 16 September 2014 09:01

Response to Price Query for Clinuvel Pharmaceuticals Ltd

Thursday, 11 September 2014 19:03

Form 604

Monday, 25 August 2014 08:19

Appendix 4E - Preliminary Final Report 2013/14

Page 1 of 35

Share Price

Buy : 2.55

Sell : 2.65

First : 2.35

Last : 2.62

High : 2.62

Low : 2.35

ASX: CUV 20 mins delay.

Volume : 104,918 Trades: 54

Last Traded : 23-Oct-2014 16:10:37

Popular Articles

Investor Spotlight

Clinuvel Stock Ticker

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE...

Investors' Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Related Webcasts

What can vitiligo patients do? - Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

The future of vitiligo treatment - Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Vitiligo trials of SCENESSE® - Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Quick Links